About

John McCamant joined the Medical Technology Stock Letter as associate editor in 1987 and was named editor of this leading investment newsletter in August 2000. He has spent 25 years on the front lines of biotechnology investing. As an equities analyst for the American Healthcare Fund, Mr. McCamant uncovered investment opportunities and guided investment strategy. At Burrill & Company, a San Francisco-based private merchant bank, he was a lead in raising $75 million for a venture capital fund. Mr. McCamant has established an extensive network that includes contacts throughout the investment banking and venture capital communities. His expertise in biotechnology investments is a subject of media interest, and he is frequently consulted and quoted by The Washington Post, Business Week, Reuters, Bloomberg, and CBS Marketwatch.

Meet John McCamant

The MoneyShow San Francisco Image

San Francisco Marriott Marquis

Content from John McCamant

Esperion: "The New Kid in Town"
John McCamant

Cardiovascular disease remains the world's number one killer and one of the largest pharmaceutical markets, explains biotech ex...

Tickers: ESPR | PFE
Incyte: Best in Class?
John McCamant

Incyte (INCY) and their partner Lilly announced that the European Commission has granted marketing authorisation for Olumiant (...

Tickers: INCY
Intrexon: Chimeras, CRSPR and Gene Therapy
John McCamant

Intrexon (XON) has made a small yet strategic acquisition in buying GenVec (GNVC); with the purchase, XON gets AdenoVerse, a pl...

Tickers: XON
Top Picks 2017: Madgrigal
John McCamant

Non-alcoholic steatohepatitis, or NASH, is one of the largest disease opportunities we have ever seen, explains John McCamant,...

Tickers: MDGL
Top Picks 2017: Incyte
John McCamant

This Top Pick for 2017 may very well have the best and broadest early-stage oncology pipeline with 12 drug development candidat...

Tickers: INCY
Church & Dwight: Tops among Splits
John McCamant

Each month, Neil Macneale assessing all stocks that have announced upcoming stock splits; from those, he chooses one stock to b...

Tickers: CHD
Biotech: A Perfect Storm?
John McCamant

The Trump victory has brought a V-shaped reaction to the biotech sector; while it is still very early to make definitive conclu...

Tickers: IONS | INCY | ACAD | MDCO
Incyte: A Promising Pipeline
John McCamant

John McCamant, editor The Medical Technology Stock Letter, reviews a favored biotech stocks, noting that the company will have...

Tickers: INCY